Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
出版年份 2017 全文链接
标题
Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
作者
关键词
Non-small cell lung cancer, Cancer hotspot panel, Clinical sequencing, JAK2, JAK3, Immunotherapy
出版物
Genome Medicine
Volume 9, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-10-19
DOI
10.1186/s13073-017-0478-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular definition of a metastatic lung cancer state reveals a targetable CD109–Janus kinase–Stat axis
- (2017) Chen-Hua Chuang et al. NATURE MEDICINE
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease
- (2017) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
- (2016) Mark M. Awad et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma
- (2016) Shiyong Li et al. Journal of Thoracic Oncology
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib plus trametinib in patients with previously treated BRAF V600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
- (2016) Joshua D Campbell et al. NATURE GENETICS
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials
- (2016) James H. Suh et al. ONCOLOGIST
- JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
- (2016) Sizhi P. Gao et al. Science Signaling
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
- (2016) Sizhi P. Gao et al. Science Signaling
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
- (2015) D. P. Steensma et al. BLOOD
- Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations
- (2015) Katsuhiro Masago et al. BMC CANCER
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Identification of a Novel Pathogenic Germline KDR Variant in Melanoma
- (2015) I. P. Silva et al. CLINICAL CANCER RESEARCH
- Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
- (2015) Oliver Gautschi et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Comprehensive genomic profiles of small cell lung cancer
- (2015) Julie George et al. NATURE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas
- (2015) Kui Wu et al. Nature Communications
- NCI Prepares to Launch MATCH Trial
- (2015) Cancer Discovery
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation
- (2015) E. M. Van Allen et al. Cancer Immunology Research
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
- (2014) Marcin Imielinski et al. JOURNAL OF CLINICAL INVESTIGATION
- Comprehensive molecular profiling of lung adenocarcinoma
- (2014) Eric A. Collisson et al. NATURE
- Age-related mutations associated with clonal hematopoietic expansion and malignancies
- (2014) Mingchao Xie et al. NATURE MEDICINE
- Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
- (2014) Giulio Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
- (2014) Siddhartha Jaiswal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
- (2013) Youngwook Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- Janus Kinase Deregulation in Leukemia and Lymphoma
- (2012) Edwin Chen et al. IMMUNITY
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies
- (2012) Doron Lipson et al. NATURE MEDICINE
- Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
- (2012) Wanjuan Yang et al. NUCLEIC ACIDS RESEARCH
- JAK/STAT signaling in hematological malignancies
- (2012) W Vainchenker et al. ONCOGENE
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to Dasatinib
- (2012) B. Sen et al. Science Translational Medicine
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Is the JAK2V617Fmutation detectable in healthy volunteers?
- (2009) Christophe Martinaud et al. AMERICAN JOURNAL OF HEMATOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started